Summary
- Current Price
- As of today, ROIV price is $36.20, down -0.22% on
- Current Price All-Time High
- ROIV price is currently -2.16% below its historical high of $37.00 set on
- Market Cap
- ROIV current market cap is $26B, up +226.19% over the past 365 days
- Revenue
- ROIV current annual revenue is $8.26M, down -71.57% year-over-year
- Next Earnings
- The next earnings release for ROIV is on
Profile
| Metric | Value |
|---|---|
| Full Name | Roivant Sciences Ltd. |
| Ticker | NASDAQ: ROIV |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United Kingdom |
| IPO | |
| Indexes | Not included |
| Website | roivant.com |
| Employees | 750 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $36.20 | |
| Price, 1D Change | -0.22% | |
| Market Cap | $26B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.06 | |
| Revenue | $8.26M | |
| Revenue, 1Y Change | -71.57% | |
| EPS | -$0.43 | |
| EPS, 1Y Change | -82.20% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$0.43 | |
| EPS Estimate | -$1.58 | N/A |
| EPS Est. Change | -265.83% | N/A |
| Revenue | $8.26M | |
| Revenue Estimate | $54.73M | N/A |
| Revenue Est. Change | +562.54% | N/A |
| Current Price | $36.20 | |
| Price Target | $41.00 | - |
| Price Tgt. Change | +13.26% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.57 | -$0.24 | +58.40% | |
| -$1.05 | -$0.43 | +58.66% | |
| -$1.58 | N/A | -265.83% | |
| -$1.72 | N/A | -297.62% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $141.31M | $29.05M | -79.44% | |
| $9.05M | $8.26M | -8.68% | |
| $54.73M | N/A | +562.54% | |
| $404.21M | N/A | +4,793.60% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +208.09% | |
| Price, 3Y | +209.14% | |
| Market Cap, 1Y | +226.19% | |
| Market Cap, 3Y | +191.08% | |
| Revenue, 1Y | -71.57% | |
| Revenue, 3Y | -86.52% | |
| EPS, 1Y | -82.20% | |
| EPS, 3Y | +69.48% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $36.20 | |
| SMA 200 | $27.23 | |
| SMA 50 | $33.54 | |
| EMA 200 | $27.50 | |
| EMA 50 | $33.64 | |
| MACD | $0.63 | |
| Beta | 1.06 | |
| ATR | $1.20 | |
| 14-Day RSI | 60.08 | |
| 10-Day Volatility | 31.83% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $8.26M | |
| EPS | -$0.43 | |
| Gross Profit | $3.63M | |
| Gross Margin | 43.91% | |
| Operating Income | -$1.27B | |
| Operating Margin | -15.35% | |
| Net Income | -$397.91M | |
| Net Margin | -4,817.28% | |
| EBITDA | -$1.26B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.02 | |
| 18.37 | ||
| 18.37 | ||
| - | ||
| 0 | ||
| 36.19 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 3,471.60 | ||
| 6.18 | ||
| -16.43 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $4.53B | |
| $4.30B | ||
| $5.73B | ||
| $5.17B | ||
| $435.63M | ||
| $281.24M | ||
| Total Debt | $107.44M | |
| $11.15M | ||
| $18.00M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $308.03M | ||
| $1.27B | ||
| $4.63M | ||
| $0.00 | ||
| $3.35M | ||
| $0.00 | ||
| $133.33M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| -$750.35M | ||
| -$682.33M | ||
| $134.24M | ||
| Capex | $8.21M | |
| -$758.56M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Citigroup | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| Guggenheim | → | |
| TD Cowen | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Piper Sandler | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with ROIV
FAQ
- What is the ticker symbol for Roivant Sciences Ltd.?
- The ticker symbol for Roivant Sciences Ltd. is NASDAQ:ROIV
- Does Roivant Sciences Ltd. pay dividends?
- No, Roivant Sciences Ltd. does not pay dividends
- What sector is Roivant Sciences Ltd. in?
- Roivant Sciences Ltd. is in the Healthcare sector
- What industry is Roivant Sciences Ltd. in?
- Roivant Sciences Ltd. is in the Biotechnology industry
- What country is Roivant Sciences Ltd. based in?
- Roivant Sciences Ltd. is headquartered in United Kingdom
- When did Roivant Sciences Ltd. go public?
- Roivant Sciences Ltd. initial public offering (IPO) was on December 8, 2020
- Is Roivant Sciences Ltd. in the S&P 500?
- No, Roivant Sciences Ltd. is not included in the S&P 500 index
- Is Roivant Sciences Ltd. in the NASDAQ 100?
- No, Roivant Sciences Ltd. is not included in the NASDAQ 100 index
- Is Roivant Sciences Ltd. in the Dow Jones?
- No, Roivant Sciences Ltd. is not included in the Dow Jones index
- When was Roivant Sciences Ltd. last earnings report?
- Roivant Sciences Ltd.'s most recent earnings report was on August 6, 2026
- When does Roivant Sciences Ltd. report earnings?
- The next expected earnings date for Roivant Sciences Ltd. is November 9, 2026
Data Sources & References
- ROIV Official Website roivant.com
- ROIV Profile on Yahoo Finance finance.yahoo.com/quote/ROIV
- ROIV Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/roiv